Epysqli is paid 27.9% below Soliris

2 biosimilars bill against Soliris (J1299). On average they are paid ↓ 17.8% relative to the reference product per 2 MG in 4Q26.

Soliris (reference)
Epysqli
Bkemv

Payment limit per 2 MG, last 8 quarters. Reference product as the thick navy line, biosimilars in teal and other colors.

All products

Product	Code	CMS description	Per 2 MG	vs. reference	CMS 8% add-on note
Soliris	J1299	Inj, eculizumab, 2 mg	$43.763	Reference	–
Epysqli	Q5151	Inj, eculizumab-aagh, 2 mg	$31.547	↓ 27.9%	Yes
Bkemv	Q5152	Inj, eculizumab-aeeb, 2 mg	$40.412	↓ 7.7%	Yes

Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.